Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jan 2010

Jackman David, Pao William, Riely Gregory J, Engelman Jeffrey A, Kris Mark G, Jänne Pasi A, Lynch Thomas, Johnson Bruce E, Miller Vincent A

Abstract excerpt

Ten percent of North American patients with non-small-cell lung cancer have tumors with somatic mutations in the gene for the epidermal growth factor receptor (EGFR). Approximately 70% of patients whose lung cancers harbor somatic mutations in exons encoding the tyrosine kinase domain of EGFR experience significant tumor regressions when treated with the EGFR tyrosine kinase inhibitors (TKIs) gefitinib or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Genes, erbB-1

Share to Guidelines as Topic

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 19949011
DOI: 10.1200/JCO.2009.24.7049
PMCID: PMC3870288

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.PMID 19949011Read ↗

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Semantic proximity Read ↗

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.Semantic proximity Read ↗

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.Semantic proximity Read ↗

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.Semantic proximity Read ↗

Overcoming therapy resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations.Semantic proximity Read ↗

Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.Semantic proximity Read ↗

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.Semantic proximity Read ↗

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.Semantic proximity Read ↗

Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.Semantic proximity Read ↗

Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.